{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:21:31Z","timestamp":1792581691407,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00417-022-05833-0","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T07:03:52Z","timestamp":1663311832000},"page":"401-408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Difference in characteristics and lesion reactivation between type 3 macular neovascularization with and without subretinal fluid at baseline"],"prefix":"10.1007","volume":"261","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8121-6353","authenticated-orcid":false,"given":"Jae Hui","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Gu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"key":"5833_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/IAE.0000000000003283","volume":"42","author":"V Chaudhary","year":"2022","unstructured":"Chaudhary V, Matonti F, Zarranz-Ventura J, Stewart MW (2022) Impact of fluid compartments on functional outcomes for patients with neovascular age-related macular degeneration: a systematic literature review. Retina 42:589\u2013606","journal-title":"Retina"},{"key":"5833_CR2","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.oret.2022.02.010","volume":"6","author":"R Sacconi","year":"2022","unstructured":"Sacconi R, Forte P, Tombolini B, Grosso D, Fantaguzzi F, Pina A, Querques L, Bandello F, Querques G (2022) OCT predictors of 3-year visual outcome for type 3 macular neovascularization. Ophthalmol Retina 6:586\u2013594","journal-title":"Ophthalmol Retina"},{"key":"5833_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1089\/jop.2021.0103","volume":"38","author":"JH Kim","year":"2022","unstructured":"Kim JH, Kim JW, Kim CG (2022) Difference between the incidence of retinal fluid subtypes and their association with visual outcomes according to the types of macular neovascularization in a Korean population. J Ocul Pharmacol Ther 38:261\u2013268","journal-title":"J Ocul Pharmacol Ther"},{"key":"5833_CR4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/IAE.0000000000003371","volume":"42","author":"A Sharma","year":"2022","unstructured":"Sharma A, Cheung CMG, Arias-Barquet L, Ozdek S, Parachuri N, Kumar N, Hilely A, Zur D, Loewenstein A, Vella G, Bandello F, Querques G (2022) Fluid-based visual prognostication in type 3 macular neovascularization-flip-3 study. Retina 42:107\u2013113","journal-title":"Retina"},{"key":"5833_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/IAE.0b013e3181669504","volume":"28","author":"KB Freund","year":"2008","unstructured":"Freund KB, Ho IV, Barbazetto IA, Koizumi H, Laud K, Ferrara D, Matsumoto Y, Sorenson JA, Yannuzzi L (2008) Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina 28:201\u2013211","journal-title":"Retina"},{"issue":"Suppl 1","key":"5833_CR6","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/IAE.0b013e31823f9b3b","volume":"32","author":"LA Yannuzzi","year":"2012","unstructured":"Yannuzzi LA, Negr\u00e3o S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, Freund KB, Sorenson J, Orlock D, Borodoker N (2012) Retinal angiomatous proliferation in age\u2013related macular degeneration 2001. Retina 32(Suppl 1):416\u2013434","journal-title":"Retina"},{"issue":"Suppl 1","key":"5833_CR7","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1097\/IAE.0000000000001268","volume":"36","author":"D Su","year":"2016","unstructured":"Su D, Lin S, Phasukkijwatana N, Chen X, Tan A, Freund KB, Sarraf D (2016) An updated staging system of type 3 neovascularization using spectral domain optical coherence tomography. Retina 36(Suppl 1):S40\u2013S49","journal-title":"Retina"},{"key":"5833_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/bjophthalmol-2020-318128","volume":"105","author":"A Sharma","year":"2021","unstructured":"Sharma A, Parachuri N, Kumar N, Bandello F, Kuppermann BD, Loewenstein A, Regillo C, Chakravarthy U (2021) Fluid-based prognostication in n-AMD: type 3 macular neovascularisation needs an analysis in isolation. Br J Ophthalmol 105:297\u2013298","journal-title":"Br J Ophthalmol"},{"key":"5833_CR9","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1097\/IAE.0000000000000488","volume":"35","author":"A Nagiel","year":"2015","unstructured":"Nagiel A, Sarraf D, Sadda SR, Spaide RF, Jung JJ, Bhavsar KV, Ameri H, Querques G, Freund KB (2015) Type 3 neovascularization: evolution, association with pigment epithelial detachment, and treatment response as revealed by spectral domain optical coherence tomography. Retina 35:638\u2013647","journal-title":"Retina"},{"key":"5833_CR10","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s00417-019-04306-1","volume":"257","author":"JH Kim","year":"2019","unstructured":"Kim JH, Chang YS, Kim JW, Kim CG, Lee DW (2019) Long-term incidence and timing of reactivation in patients with type 3 neovascularization after initial treatment. Graefes Arch Clin Exp Ophthalmol 257:1183\u20131189","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5833_CR11","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00417-018-04228-4","volume":"257","author":"JH Kim","year":"2019","unstructured":"Kim JH, Chang YS, Kim JW, Kim CG, Lee DW (2019) Age-related differences in the prevalence of subtypes of neovascular age-related macular degeneration in the first diagnosed eye. Graefes Arch Clin Exp Ophthalmol 257:891\u2013898","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5833_CR12","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.survophthal.2017.01.008","volume":"62","author":"ASH Tsai","year":"2017","unstructured":"Tsai ASH, Cheung N, Gan ATL, Jaffe GJ, Sivaprasad S, Wong TY, Cheung CMG (2017) Retinal angiomatous proliferation. Surv Ophthalmol 62:462\u2013492","journal-title":"Surv Ophthalmol"},{"key":"5833_CR13","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1097\/IAE.0000000000002239","volume":"39","author":"JH Kim","year":"2019","unstructured":"Kim JH, Chang YS, Kim JW, Kim CG, Lee DW, Kim HS (2019) Long-term visual changes in initially stronger fellow eyes in patients with unilateral type 3 neovascularization. Retina 39:1672\u20131681","journal-title":"Retina"},{"key":"5833_CR14","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1136\/bjophthalmol-2018-312944","volume":"103","author":"A Invernizzi","year":"2019","unstructured":"Invernizzi A, Teo K, Nguyen V, Daniell M, Squirrell D, Barthelmes D, Gillies MC (2019) Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months. Br J Ophthalmol 103:1337\u20131341","journal-title":"Br J Ophthalmol"},{"key":"5833_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","volume":"124","author":"JE Grunwald","year":"2017","unstructured":"Grunwald JE, Pistilli M, Daniel E, Ying GS, Pan W, Jaffe GJ, Toth CA, Hagstrom SA, Maguire MG, Martin DF (2017) Incidence and growth of geographic atrophy during 5 years of comparison of age-related macular degeneration treatments trials. Ophthalmol 124:97\u2013104","journal-title":"Ophthalmol"},{"key":"5833_CR16","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3390\/jcm9041145","volume":"9","author":"JH Kim","year":"2020","unstructured":"Kim JH, Kim JW, Kim CG, Lee DW (2020) Long-term treatment outcomes in type 3 neovascularization: focus on the difference in outcomes between geographic atrophy and fibrotic scarring. J Clin Mid 9:1145","journal-title":"J Clin Mid"},{"key":"5833_CR17","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","volume":"35","author":"KB Freund","year":"2015","unstructured":"Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, Hoerauf H, Lanzetta P, Michels S, Mitchell P, Mones J, Regillo C, Tadayoni R, Talks J, Wolf S (2015) Treat-and-extend regimens with anti-vegf agents in retinal diseases: a literature review and consensus recommendations. Retina 35:1489\u20131506","journal-title":"Retina"},{"key":"5833_CR18","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1097\/IAE.0000000000002774","volume":"40","author":"B Haj Najeeb","year":"2020","unstructured":"Haj Najeeb B, Deak G, Schmidt-Erfurth U, Gerendas BS (2020) The RAP STUDY, REPORT TWO: the regional distribution of macular neovascularization type 3, a novel insight into its etiology. Retina 40:2255\u20132262","journal-title":"Retina"},{"key":"5833_CR19","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1097\/IAE.0000000000002489","volume":"40","author":"JH Kim","year":"2020","unstructured":"Kim JH, Chang YS, Kim JW, Kim CG, Lee DW (2020) Characteristics of type 3 neovascularization lesions: focus on the incidence of multifocal lesions and the distribution of lesion location. Retina 40:1124\u20131131","journal-title":"Retina"},{"key":"5833_CR20","doi-asserted-by":"publisher","unstructured":"Rosenberg D, Deonarain DM, Gould J, Sothivannan A, Phillips MR, Sarohia GS, Sivaprasad S, Wykoff CC, Cheung CMG, Sarraf D, Bakri SJ, Chaudhary V (2022) Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye (Lond). https:\/\/doi.org\/10.1038\/s41433-022-02020-7","DOI":"10.1038\/s41433-022-02020-7"},{"key":"5833_CR21","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1097\/IAE.0000000000002582","volume":"40","author":"L Arias","year":"2020","unstructured":"Arias L, Cervera E, Vilimelis JC, Escobar JJ, Escobar AG, Zapata M (2020) Efficacy and safety of a treat-and-extend regimen with aflibercept in treatment-naive patients with type 3 neovascularization: a 52-week, single-arm, multicenter trial. Retina 40:1234\u20131244","journal-title":"Retina"},{"key":"5833_CR22","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1097\/IAE.0000000000000225","volume":"34","author":"JY Shin","year":"2014","unstructured":"Shin JY, Yu HG (2014) Optical coherence tomography-based ranibizumab monotherapy for retinal angiomatous proliferation in Korean patients. Retina 34:2359\u20132366","journal-title":"Retina"},{"key":"5833_CR23","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1097\/IAE.0b013e3181bfbd46","volume":"29","author":"M Engelbert","year":"2009","unstructured":"Engelbert M, Zweifel SA, Freund KB (2009) \u201cTreat and extend\u201d dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization\/retinal angiomatous proliferation. Retina 29:1424\u20131431","journal-title":"Retina"},{"key":"5833_CR24","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/IAE.0b013e3181fe54c7","volume":"31","author":"VA McBain","year":"2011","unstructured":"McBain VA, Kumari R, Townend J, Lois N (2011) Geographic atrophy in retinal angiomatous proliferation. Retina 31:1043\u20131052","journal-title":"Retina"},{"key":"5833_CR25","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ophtha.2019.11.010","volume":"127","author":"SR Sadda","year":"2020","unstructured":"Sadda SR, Guymer R, Mon\u00e9s JM, Tufail A, Jaffe GJ (2020) Anti-vascular endothelial growth factor use and atrophy in neovascular age-related macular degeneration: systematic literature review and expert opinion. Ophthalmol 127:648\u2013659","journal-title":"Ophthalmol"},{"key":"5833_CR26","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1136\/bjophthalmol-2013-304405","volume":"98","author":"JH Kim","year":"2014","unstructured":"Kim JH, Lee TG, Kim JW, Kim CG, Cho SW, Han JI (2014) Small retinal haemorrhages accompanied by macular soft drusen: prevalence, and funduscopic and angiographic characteristics. Br J Ophthalmol 98:1066\u20131072","journal-title":"Br J Ophthalmol"},{"key":"5833_CR27","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1097\/IAE.0000000000002412","volume":"39","author":"RF Spaide","year":"2019","unstructured":"Spaide RF (2019) New proposal for the pathophysiology of type 3 neovascularization as based on multimodal imaging findings. Retina 39:1451\u20131464","journal-title":"Retina"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05833-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-022-05833-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05833-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T07:16:18Z","timestamp":1673507778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-022-05833-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["5833"],"URL":"https:\/\/doi.org\/10.1007\/s00417-022-05833-0","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]},"assertion":[{"value":"6 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Kim\u2019s Eye Hospital (Seoul, South Korea) and conducted in accordance with the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not obtained as no participant information was identified in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}